{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T06:32:46Z","timestamp":1786689166885,"version":"build-2736575974"},"reference-count":30,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>Hepatic osteodystrophy is defined as a metabolic bone disease that may occur in individuals with chronic liver disease (CLD). Hepatic osteodystrophy commonly manifests with osteoporosis and fragility fractures. This review finds that patients older than 50 years with CLD should be screened for possible osteoporosis earlier if they experience fragility fractures. Treatment includes calcium, vitamin D, and lifestyle interventions. Bisphosphonates, such as alendronate, and denosumab increase bone mineral density in CLD patients.<\/jats:p>","DOI":"10.61409\/v12230769","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:24:28Z","timestamp":1780986268000},"page":"1-7","source":"Crossref","is-referenced-by-count":0,"title":["Osteodystrophy in chronic liver disease"],"prefix":"10.61409","author":[{"given":"Pia","family":"Eiken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atheer Adel","family":"Al-Omran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank Vinholt","family":"Schi\u00f8dt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"40208","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Gatta A, Verardo A, Di Pascoli M et al. Hepatic osteodystrophy. Clin Cases Miner Bone Metab. 2014;11(3):185-91. https:\/\/doi.org\/10.11138\/ccmbm\/2014.11.3.185","DOI":"10.11138\/ccmbm\/2014.11.3.185"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Pramanik S, Palui R, Ray S. Hepatic osteodystrophy: an underrecognized metabolic bone disease. World J Hepatol. 2025;17(8):109093. https:\/\/doi.org\/10.4254\/wjh.v17.i8.109093","DOI":"10.4254\/wjh.v17.i8.109093"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Ehnert S, Aspera-Werz RH, Ruo\u00df M et al. Hepatic osteodystrophy-molecular mechanisms proposed to favor its development. Int J Mol Sci. 2019;20(10):2555. https:\/\/doi.org\/10.3390\/ijms20102555","DOI":"10.3390\/ijms20102555"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Barbu EC, Chi\u021bu-Ti\u0219u C, Laz\u0103r M et al. Hepatic osteodystrophy: a global (re)view of the problem. Acta Clin Croat. 2017;56(3):512-525. https:\/\/doi.org\/10.20471\/acc.2017.56.03.19","DOI":"10.20471\/acc.2017.56.03.19"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Kang J, Gopakumar H, Puli SR. Prevalence of osteoporosis in cirrhosis: a systematic review and meta-analysis. Cureus. 2023;15(1):e33721. https:\/\/doi.org\/10.7759\/cureus.33721","DOI":"10.7759\/cureus.33721"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70(1):172-193. https:\/\/doi.org\/10.1016\/j.jhep.2018.06.024","DOI":"10.1016\/j.jhep.2018.06.024"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Gao H, Peng X, Li N et al. Emerging role of liver-bone axis in osteoporosis. J Orthop Translat. 2024;48:217-231. https:\/\/doi.org\/10.1016\/j.jot.2024.07.008","DOI":"10.1016\/j.jot.2024.07.008"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Guichelaar MMJ, Malinchoc M, Sibonga J et al. Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry. Hepatology. 2002;36(4 Pt 1):895-903. https:\/\/doi.org\/10.1053\/jhep.2002.36357","DOI":"10.1053\/jhep.2002.36357"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Katsaounis PV, Hadjiyannis ES, Skaltsi T et al. Bone disease in patients with cirrhosis of different etiology and severity: are klotho protein and osteoprotegerin potential biomarkers? Scand J Gastroenterol. 2023;58(2):185-192. https:\/\/doi.org\/10.1080\/00365521.2022.2114813","DOI":"10.1080\/00365521.2022.2114813"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Santos LAA, Romeiro FG. Diagnosis and management of cirrhosis-related osteoporosis. Biomed Res Int. 2016;2016:1423462. https:\/\/doi.org\/10.1155\/2016\/1423462","DOI":"10.1155\/2016\/1423462"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Gallego-Rojo F, Gonzalez-Calvin J, Mu\u00f1oz-Torres M et al. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology. 1998;28(3):695-699. https:\/\/doi.org\/10.1002\/hep.510280315","DOI":"10.1002\/hep.510280315"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Sobh MM, Abdalbary M, Elnagar S et al. Secondary osteoporosis and metabolic bone diseases. J Clin Med. 2022;11(9):2382. https:\/\/doi.org\/10.3390\/jcm11092382","DOI":"10.3390\/jcm11092382"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on the management of autoimmune hepatitis. J Hepatol. 2025;83(2):453-501. https:\/\/doi.org\/10.1016\/j.jhep.2025.03.017","DOI":"10.1016\/j.jhep.2025.03.017"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Shirinezhad A, Eshlaghi FM, Salabat D et al. Prevalent osteoporosis and fracture risk in patients with hepatic cirrhosis: a systematic review and meta-analysis. BMC Gastroenterol. 2025;25(1):115. https:\/\/doi.org\/10.1186\/s12876-025-03720-6","DOI":"10.1186\/s12876-025-03720-6"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Bang UC, Benfield T, Bendtsen F et al. The risk of fractures among patients with cirrhosis or chronic pancreatitis. Clin Gastroenterol Hepatol. 2014;12(2):320-6. https:\/\/doi.org\/10.1016\/j.cgh.2013.04.031","DOI":"10.1016\/j.cgh.2013.04.031"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Otete H, Deleuran T, Fleming KM et al. Hip fracture risk in patients with alcoholic cirrhosis: a population-based study using English and Danish data. J Hepatol. 2018;69(3):697-704. https:\/\/doi.org\/10.1016\/j.jhep.2018.04.002","DOI":"10.1016\/j.jhep.2018.04.002"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Sch\u00f6nau J, Wester A, Schattenberg JM, Hagstr\u00f6m H. Risk of fractures and postfracture mortality in 3980 people with primary biliary cholangitis: a population-based cohort study. J Intern Med. 2023;294(2):164-177. https:\/\/doi.org\/10.1111\/joim.13624","DOI":"10.1111\/joim.13624"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Lim J, Kim YJ, Kim S, Choi J. Increased risk of fragility fractures in patients with primary biliary cholangitis. JBMR Plus. 2024;8(7):ziae056. https:\/\/doi.org\/10.1093\/jbmrpl\/ziae056","DOI":"10.1093\/jbmrpl\/ziae056"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Gua\u00f1abens N, Cerd\u00e1 D, Monegal A et al. Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis. Gastroenterology. 2010;138(7):2348-56. https:\/\/doi.org\/10.1053\/j.gastro.2010.02.016","DOI":"10.1053\/j.gastro.2010.02.016"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Yurci A, Kalkan AO, Ozbakir O et al. Efficacy of different therapeutic regimens on hepatic osteodystrophy in chronic viral liver disease. Eur J Gastroenterol Hepatol. 2011;23(12):1206-12. https:\/\/doi.org\/10.1097\/MEG.0b013e32834cd6f6","DOI":"10.1097\/MEG.0b013e32834cd6f6"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Zein CO, Jorgensen RA, Clarke B et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology. 2005;42(4):762-71. https:\/\/doi.org\/10.1002\/hep.20866","DOI":"10.1002\/hep.20866"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Lima TB, Santos LAA, Nunes HRdC et al. Safety and efficacy of risedronate for patients with esophageal varices and liver cirrhosis: a non-randomized clinical trial. Sci Rep. 2019;9(1):18958. https:\/\/doi.org\/10.1038\/s41598-019-55603-y","DOI":"10.1038\/s41598-019-55603-y"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Raj H, Kamalanathan S, Sahoo J et al. Effect of zoledronic acid in hepatic osteodystrophy: a double-blinded placebo-controlled trial. Indian J Endocrinol Metab. 2023;27(6):552-558. https:\/\/doi.org\/10.4103\/ijem.ijem_233_23","DOI":"10.4103\/ijem.ijem_233_23"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Arase Y, Okubo T, Arai T et al. Denosumab versus zoledronic acid for osteoporosis treatment in patients withs primary biliary cholangitis (the DELTA Study): a multicenter, non-inferiority randomized trial. Hepatol Commun. 2025;9(11):e0827. https:\/\/doi.org\/10.1097\/HC9.0000000000000827","DOI":"10.1097\/HC9.0000000000000827"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Gua\u00f1abens N, Monegal A, Cerd\u00e1 D et al. Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. Hepatology. 2013;58(6):2070-8. https:\/\/doi.org\/10.1002\/hep.26466","DOI":"10.1002\/hep.26466"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Gua\u00f1abens N, Par\u00e9s A, Ros I et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol. 2003;98(10):2268-74. https:\/\/doi.org\/10.1111\/j.1572-0241.2003.07639.x","DOI":"10.1111\/j.1572-0241.2003.07639.x"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Saeki C, Saito M, Oikawa T et al. Effects of denosumab treatment in chronic liver disease patients with osteoporosis. World J Gastroenterol. 2020;26(33):4960-4971. https:\/\/doi.org\/10.3748\/wjg.v26.i33.4960","DOI":"10.3748\/wjg.v26.i33.4960"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Arase Y, Tsuruya K, Hirose S et al. Efficacy and safety of 3-year denosumab therapy for osteoporosis in patients with autoimmune liver diseases. Hepatology. 2020;71(2):757-759. https:\/\/doi.org\/10.1002\/hep.30904","DOI":"10.1002\/hep.30904"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Levy C, Harnois DM, Angulo P et al. Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study. Liver Int. 2005;25(1):117-21. https:\/\/doi.org\/10.1111\/j.1478-3231.2005.01026.x","DOI":"10.1111\/j.1478-3231.2005.01026.x"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Ormarsd\u00f3ttir S, Mallmin H, Naess\u00e9n T et al. An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis. J Intern Med. 2004;256(1):63-9. https:\/\/doi.org\/10.1111\/j.1365-2796.2004.01342.x","DOI":"10.1111\/j.1365-2796.2004.01342.x"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T06:19:40Z","timestamp":1786688380000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V12230769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":30,"URL":"https:\/\/doi.org\/10.61409\/v12230769","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"value":"0041-5782","type":"print"},{"value":"1603-6824","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]}}}